Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD Disclosure |
Inotek Pharmaceuticals Corporation (the Company) is furnishing an
investor presentation, attached as Exhibit 99.1 to this Report on
Form 8-K, which the Company intends to use from time to time in
meetings with investors and others beginning on November29, 2016.
The investor presentation will also be available on the Companys
website at http://ir.inotekpharma.com.
The information in this Report on Form 8-K and Exhibit 99.1
attached hereto is intended to be furnished and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934 (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or
the Exchange Act, except as expressly set forth by specific
reference in such filing.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
|
| 99.1 |
Inotek Pharmaceuticals Corporation November 2016 Corporate Presentation. |
About Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases. Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Recent Trading Information
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) closed its last trading session 00.00 at 6.25 with 837,638 shares trading hands.
